Breast Cancer

Sequential Use Of Doxorubicin And Docetaxel Produce High Pathologic Response Rate

Published in Cancer Weekly, January 15th, 2002

Researchers at H. Lee Moffitt Cancer Center and Research Institute have found that dose-dense sequential administration of neoadjuvant docetaxel (Taxotere) and doxorubicin (Adriamycin) produced a 24% complete pathologic response rate (no evidence of tumor or tumor cells in the breast at time of surgery) in patients with locally advanced breast cancer.

Preliminary data from this phase II study were presented December 13, 2001, at the 24th annual San Antonio Breast Cancer Symposium held in Texas.

"Docetaxel is highly active in advanced breast cancer, with a response rate as second-line therapy that is similar to doxorubicin as first-line therapy,"...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-01-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry